NCT01007409

Brief Summary

To assess food effect on the pharmacokinetics of fimasartan in healthy male volunteers.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at P25-P50 for phase_1 healthy

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2009

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

November 2, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 4, 2009

Completed
Last Updated

December 24, 2009

Status Verified

December 1, 2009

Enrollment Period

1 month

First QC Date

November 2, 2009

Last Update Submit

December 23, 2009

Conditions

Keywords

To assess food effect on the pharmacokinetics of fimasartan in healthy male volunteers

Outcome Measures

Primary Outcomes (1)

  • Cmax, Tmax, AUC, T1/2, CL/F etc.

    0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours

Study Arms (2)

Group B

ACTIVE COMPARATOR

Period 1: fed control → Period 2: fasted control

Drug: Fimasartan

Group A

ACTIVE COMPARATOR

Period 1: fasted control → Period 2: fed control

Drug: Fimasartan

Interventions

Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast

Group B

Eligibility Criteria

Age20 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • age: 20 - 45 years
  • sex: male
  • body weight: greater than 55 kg
  • written informed consent

You may not qualify if:

  • known allergy to Fimasartan
  • existing cardiac or hematological diseases
  • existing hepatic and renal diseases
  • existing gastrointestinal diseases
  • acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder
  • abnormal diet which could affect drug absorption or metabolism
  • positive drug or alcohol screening
  • smokers of 10 or more cigarettes per day
  • participation in a clinical trial during the last 60 days prior to the start of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

fimasartan

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 2009

First Posted

November 4, 2009

Study Start

October 1, 2009

Primary Completion

November 1, 2009

Last Updated

December 24, 2009

Record last verified: 2009-12